自动化一站式呼吸道病原核酸检测平台在县域医院本地化应用的探索
摘要
用价值。方法 选取 2023 年 7 月至 2024 年 1 月临床诊断为 CAP 的住院患者 72 例，采集肺泡灌洗液（44 例）和痰液（28 例）
标本。所有标本采用 iChip-400 检测，BALF 标本同时行靶向测序（tNGS）检测，并行常规涂片和培养。以临床综合诊断
为 " 金标准 "，比较各方法的病原体检出率、检测效能及检测时间。结果 iChip-400 检测时间显著短于 tNGS 和培养，在两
类样本中均表现出较好的诊断优势。对肺炎支原体和肺炎链球菌具有高灵敏度和阳性预测值。结论 iChip-400 平台快速、
自动化、操作简便，对常见 CAP 病原体检测灵敏度高，适用于县域医院，有助于实现早期病原诊断和抗菌药物合理应用。
关键词
全文:
PDF参考
[1]Lapa, S.A., et al., Development of Multiplex RT-PCR
with Immobilized Primers for Identification of Infectious Human
Pneumonia Pathogens. Mol Biol, 2021. 55(6): p. 828-838.
[2].Abelenda-Alonso, G., et al., Impact of comprehensive
molecular testing to reduce antibiotic use in community-acquired
pneumonia (RADICAP): a randomised, controlled, phase IV
clinical trial protocol. BMJ Open, 2020. 10(8): p. e038957.
[3]Kerneis, S., et al., Molecular diagnostic methods for
pneumonia: how can they be applied in practice? Curr Opin Infect
Dis, 2021. 34(2): p. 118-125.
[4]Shrestha, A., A. Georgiou, and N. Wabe, Timeliness
of Microbiology Test Result Reporting and Association with
Outcomes of Adults Hospitalised with Unspecified Pneumonia: A
Data Linkage Study. Int J Clin Pract, 2022. 2022: p. 9406499.
[5] 吕晶南 , 余方友 . 分子生物学技术在感染性疾病诊断
中的应用进展 [J]. 临床检验杂志 ,2021,39(02):81-85.
[6]Gerace, E., et al., Recent Advances in the Use of
Molecular Methods for the Diagnosis of Bacterial Infections.
Pathogens, 2022. 11(6).
[7] 金君 , 孙仁华 , 呼邦传 . 血流感染的分子诊断研究进
展 [J]. 中国现代医生 ,2020,58(36):182-187.
[8] 杨萍 , 徐逸鸣 , 冯芳 , 等 . 基层医院病原菌的分布及
感染控制 [J]. 中华医院感染学杂志 ,2010,20(21):3412-3413..
[9].Zhu, H., et al., PCR past, present and future.
Biotechniques, 2020. 69(4): p. 317-325.
[10] 黄晓园 , 郑凯文 , 张俊杰 , 等 . 基于多重 PCR 靶向
测序技术建立临床病原菌检测方法 [J]. 分子诊断与治疗杂
志 ,2023,15(09):1473-1477.
[11].Walter, J.M. and R.G. Wunderink, Testing for
Respiratory Viruses in Adults With Severe Lower Respiratory
Infection. Chest, 2018. 154(5): p. 1213-1222.
[12].Luchsinger, V., et al., Comparison of Luminex xTAG®
RVP fast assay and real time RT-PCR for the detection of
respiratory viruses in adults with community-acquired pneumonia.
J Med Virol, 2016. 88(7): p. 1173-9.
[13]Calabretta, D., I. Martìn-Loeches, and A. Torres, New
Guidelines for Severe Community-acquired Pneumonia. Semin
Respir Crit Care Med, 2024. 45(2): p. 274-286.
[14].Eshwara, V.K., C. Mukhopadhyay, and J. Rello,
Community-acquired bacterial pneumonia in adults: An update.
Indian J Med Res, 2020. 151(4): p. 287-302.
[15].Hogerwerf, L., et al., Chlamydia psittaci (psittacosis) as a
cause of community-acquired pneumonia: a systematic review and
meta-analysis. Epidemiol Infect, 2017. 145(15): p. 3096-3105.
[16].Serigstad, S., et al., Impact of rapid molecular testing
on diagnosis, treatment and management of community-acquired
pneumonia in Norway: a pragmatic randomised controlled
trial(CAPNOR). Trials, 2022. 23(1): p. 622.
[17]Zhang, P., et al., Clinical application of targeted next-
generation sequencing in severe pneumonia: a retrospective
review. Crit Care, 2024. 28(1): p. 225.
(2 摘要 Views, 5 PDF Downloads)
Refbacks
- 当前没有refback。